NCT03985072View on ClinicalTrials.gov

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

April 26, 2019

Primary Completion Date

February 17, 2022

Study Completion Date

February 17, 2022

Conditions
Tumor, SolidGall Bladder CancerCervical CancerGastric CancerPancreatic CancerColorectal Cancer
Interventions
DRUG

Andes-1537 for Injection

Andes-1537 administered subcutaneously five days per week.

Trial Locations (4)

2540364

Centro de Investigaciones Clinicas Vina del Mar, Viña del Mar

7500921

Fundacion Arturo Lopez Perez, Santiago

8330032

Centro de Cancer de Nuestra Senora de la Esperanza, Red de Salud UC CHRISTUS, Santiago

8380455

Instituto Nacional del Cáncer (INCANCER), Santiago

Sponsors
All Listed Sponsors
lead

Andes Biotechnologies

INDUSTRY

NCT03985072 - Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor | Biotech Hunter | Biotech Hunter